NGM Biopharmaceuticals

• NCT03298464

  Phase 1, Completed, 25 people, 2 Oct 2017

• Proteomic signatures during pregnancy: an exploratory cohort study of long-term health indicators

  Consulting or advice, Patents or royalties, Board or leadership role, 22 Sept 2026

• Geometric Aging of the Thoracic Aorta: Insights From 2 Large Cohorts

  Consulting or advice, 11 Sept 2025

• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

  Grants or research support, 27 Jun 2021

Sources: pubmed.ncbi.nlm.nih.gov